Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.
The review found no eligible studies for this question.
It is very uncertain whether erythromycin plus nasogastric tube lavage changes all‐cause mortality compared with no intervention/placebo plus nasogastric tube lavage (very low certainty).
It is very uncertain whether erythromycin plus nasogastric tube lavage changes NSAEs compared with no intervention/placebo plus nasogastric tube lavage (very low certainty).
It is very uncertain whether erythromycin plus nasogastric tube lavage changes rebleeding compared with no intervention/placebo plus nasogastric tube lavage (very low certainty).
It is very uncertain whether erythromycin changes SAEs compared with placebo (very low certainty).
It is very uncertain whether erythromycin changes all‐cause mortality compared with placebo (very low certainty).
It is very uncertain whether erythromycin changes NSAEs compared with placebo (very low certainty).
It is very uncertain whether erythromycin changes rebleeding compared with placebo (very low certainty).
It is very uncertain whether superoxide dismutase (SOD) changes BPD defined as an oxygen requirement at 28 days№ of participants:… compared with placebo (very low certainty).
It is very uncertain whether superoxide dismutase (SOD) changes BPD defined as oxygen at 36 weeks' postmenstrual age№ of… compared with placebo (very low certainty).
It is very uncertain whether superoxide dismutase (SOD) changes neonatal mortality (i.e. within 28 days)№ of participants: 335(2 RCTs) compared with placebo (very low certainty).
It is very uncertain whether superoxide dismutase (SOD) changes mortality prior to discharge№ of participants: 78(2 RCTs) compared with placebo (very low certainty).
The review found no eligible studies for this question.